You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
28 June 2022
MOLOGEN AG: Insolvenzplan der Mologen AG bestätigt
31 January 2022
MOLOGEN AG: Insolvenzplanverfahren
6 November 2020
MOLOGEN AG: Widerruf der Zulassung zum regulierten Markt
8 May 2020
MOLOGEN AG: Sale of the essential assets
30 April 2020
MOLOGEN AG: Resignation of all Management and Supervisory Board members
23 April 2020
MOLOGEN AG: Revocation of admission to Prime Standard
3 February 2020
MOLOGEN AG: Opening of insolvency proceedings
3 January 2020
12 December 2019
3 December 2019
MOLOGEN AG: Insolvency Filing
2 December 2019
MOLOGEN AG: Update on short-term financing of the Company
30 November 2019
Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
22 November 2019
MOLOGEN AG: Issuance of a convertible bond with exclusion of shareholders’ subscription rights
15 November 2019
12 November 2019
7 November 2019
MOLOGEN AG: Focusing on combination therapies
4 November 2019
MOLOGEN AG announces start of phase IIa TITAN combination study in HIV
1 November 2019
30 October 2019
8 October 2019
MOLOGEN AG: Cooperation with amfAR Institute for HIV Cure Research on clinical combination trial
30 September 2019
MOLOGEN AG: Update on development status of lead product candidates
13 September 2019
5 September 2019
3 September 2019
30 August 2019
MOLOGEN AG: Executive Board presents future strategy to shareholders; shareholders elect new Supervisory Board member and adopt new Authorized and Conditional Capital
29 August 2019
28 August 2019
27 August 2019
MOLOGEN AG: ‘Notice of allowance’ for US patent application in respect of combination therapies using lefitolimod and EnanDIM(R) with checkpoint inhibitors
